ROM4

PF3D7_0506900 (ROM4) is an intramembrane rhomboid serine protease that drives Plasmodium erythrocyte invasion by cleaving invasion adhesins within their transmembrane domains (PMID:17040128, PMID:17000879). In a heterologous cleavage system it processes a broad set of P. falciparum adhesins—including TRAP, CTRP, MTRAP, EBA-175, multiple EBAs (BAEBL, JESEBL, MAEBL), and Rh proteins (Rh1, Rh2a, Rh2b, Rh4)—with a substrate specificity distinct from canonical rhomboids and from its paralog ROM1; transmembrane-domain swaps between BAEBL and AMA1 reassign ROM4/ROM1 preference, showing that specificity is encoded in the adhesin TMD (PMID:17040128). ROM4 localizes to the merozoite plasma membrane, where it cleaves EBA-175 during invasion, and TMD mutations that abolish this cleavage block parasite growth, establishing its proteolytic activity as essential to the blood-stage life cycle (PMID:17000879); consistent with this, the gene is refractory to deletion in P. berghei (PMID:23490234). Its atypical specificity arises from a 'steric exclusion' mechanism in which juxtamembrane residues mutually exclude ROM4 and canonical rhomboids from each other's substrates; this feature enabled engineered peptide boronate and alpha-ketoamide inhibitors that selectively block ROM4 (but not human rhomboids), arrest merozoite invasion, and clear parasitemia in culture (PMID:32888502).

1. 2006 High

   It was unknown whether ROM4 was a functional protease and what it acted on; a heterologous assay established it as a rhomboid intramembrane protease with a distinct adhesin-directed substrate repertoire, defining its enzymatic identity.

   Evidence Heterologous rhomboid cleavage assay against multiple adhesins plus BAEBL/AMA1 transmembrane-domain swap mutagenesis

   PMID:17040128

   Open questions at the time

   • Cleavage demonstrated in a heterologous cell system, not in the native parasite for all listed substrates
   • Which of the many candidate substrates are physiologically cleaved by ROM4 during invasion was not resolved
2. 2006 High

   The subcellular site and biological necessity of ROM4 activity were unknown; localization to the merozoite plasma membrane plus a growth-lethal EBA-175 TMD cleavage mutant established that ROM4-mediated intramembrane proteolysis is essential for the life cycle.

   Evidence Immunofluorescence/fractionation localization, in vitro cleavage with EBA-175 TMD mutants, and parasite growth assays

   PMID:17000879

   Open questions at the time

   • Essentiality inferred from a substrate-side (EBA-175 TMD) mutation rather than direct ROM4 knockout
   • Timing of cleavage relative to invasion steps not precisely mapped
3. 2011 Medium

   Whether a ROM4-type transmembrane cleavage occurs on Rh-family adhesins during native invasion was open; PfRh2a was found to be cleaved in its transmembrane region with ectodomain release, consistent with ROM4 activity.

   Evidence Proteolytic cleavage analysis of PfRh2a in invasion assays, with attribution to ROM4 by TMD cleavage-site inference

   PMID:21698217

   Open questions at the time

   • Attribution to ROM4 is biochemical inference, not direct enzymatic reconstitution or mutagenesis in this study
   • Functional consequence of Rh2a cleavage for invasion not established here
4. 2013 Medium

   Direct genetic evidence for ROM4 essentiality was lacking; a systematic rhomboid deletion screen in P. berghei found the gene refractory to deletion, confirming an essential role in asexual blood-stage development independent of substrate-side mutations.

   Evidence Systematic loss-of-function gene-deletion screen across all eight rhomboids in P. berghei

   PMID:23490234

   Open questions at the time

   • Refractoriness to deletion does not itself define the essential substrate or step
   • Shown in P. berghei; direct knockout essentiality in P. falciparum not established here
5. 2020 High

   The structural basis of ROM4's parasite-selective specificity and its druggability were unknown; a 'steric exclusion' mechanism was decoded and exploited to build selective inhibitors that block invasion, validating ROM4 as an antimalarial target.

   Evidence Substrate engineering with in vitro proteolysis, high-resolution structural analysis, compound screening, and inhibitor treatment of blood-stage cultures with ultrastructural readout

   PMID:32888502

   Open questions at the time

   • In vivo efficacy of the inhibitors beyond culture not addressed
   • Resistance liability and off-target profile across the parasite proteome not defined

• The precise set of native, physiologically-cleaved ROM4 substrates during invasion and the consequences of a direct P. falciparum ROM4 knockout remain to be defined.
• No direct conditional ROM4 knockout in P. falciparum reported in the corpus
• The in vivo hierarchy among the many candidate adhesin substrates is unresolved